The role of biological response modifiers in the management of patients with colorectal cancer

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

1993 • 2,828 citations

Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma

1990 • 2,226 citations

Tumor Rejection After Direct Costimulation of CD8 ⁺ T Cells by B7-Transfected Melanoma Cells

1993 • 1,154 citations

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

1992 • 1,076 citations

Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

1989 • 1,003 citations

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.

1989 • 694 citations

Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer

1993 • 639 citations

Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.

1993 • 569 citations

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.

1994 • 482 citations

Costimulation of T cells for tumor immunity

1993 • 324 citations

Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignancies

1990 • 296 citations

Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.

1993 • 274 citations

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial.

1993 • 255 citations

Tumor antigen presentation by murine epidermal cells.

1991 • 211 citations

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.

1994 • 196 citations

Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study.

1991 • 159 citations

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experience

1993 • 134 citations

Molecular Mechanisms Used by Tumors to Escape Immune Recognition

1993 • 120 citations

A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.

1991 • 117 citations

A phase II trial of high-dose intravenous interferon alpha-2 in advanced colorectal cancer

1984 • 45 citations

Effects of Immunomodulatory Cytokines on the Presentation of Tumor-Associated Antigens by Epidermal Langerhans Cells

1992 • 39 citations

Interleukin 1α but Not Transforming Growth Factor β Inhibits Tumor Antigen Presentation by Epidermal Antigen-Presenting Cells

1994 • 35 citations

Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial.

1992 • 34 citations

Minimal activity of recombinant clone a interferon in metastatic colon cancer.

1984 • 26 citations

A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma

1989 • 20 citations

Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatment.

1985 • 19 citations

Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma.

1983 • 19 citations

High dose rDNA human alpha2 interferon therapy in patients with advanced colorectal adenocarcinoma: A phase II study

1984 • 18 citations

Fluorouracil and recombinant interferon alfa‐2a in advanced gastrointestinal neoplasms

1991 • 8 citations